Benefit not explained by urodynamics effects
Jun 1, 2009
By:Cheryl Guttman
Findings from a multicenter, randomized, double-blind, placebo-controlled study are consistent with previously reported data showing that tadalafil (Cialis) improves lower urinary tract symptoms associated with BPH.
 |
May 1, 2009
By:Zvi Gregory Wirschubsky, MD, PhD
The largest worldwide survey of acute urinary retention (AUR) ever performed suggests treatment with an alpha-blocker and trial without catheter (TWOC) within 3 days after AUR is the worldwide standard of care.
|
Symptoms improve significantly with addition of anticholinergic to alpha-blocker
May 1, 2009
By:Zvi Gregory Wirschubsky, MD, PhD
Anticholinergic drugs also are effective and safe in men who have lower urinary tract symptoms (LUTS) and bladder outlet obstruction (BOO) secondary to BPH, a new study suggests.
|
May 1, 2009
By:Michael P. O'Leary, MD
While medical therapy remains the mainstay of treatment for most men with symptomatic BPH and surgery is required for severe, progressive disease, injectables may offer a number of theoretical advantages.
|
May 1, 2009
By:Cheryl Guttman
Transperineal intraprostatic injection of a PSA-activated protoxin (PRX302) provides lasting symptomatic relief and improvement in quality of life for men with BPH, according to 1-year follow-up data from a phase I study.
|
Once-daily agent has little or no effect on cardiovascular parameters, study shows
May 1, 2009
By:Zvi Gregory Wirschubsky, MD, PhD
A new alpha-blocker for the treatment of BPH shows positive results with minimal cardiovascular side effects, according to a presentation made during the European Association of Urology annual congress
|
Mar 25, 2009
Creating a New Standard of Care for BPH Supplement for April 15, 2009 Urology Times Issue
|
Photoselective vaporization of the prostate offers reduced catheter, hospital time and more universal skill set, data show.
Sep 1, 2008
By:Patricia M. Fernberg
Men facing treatment for benign prostatic hyperplasia can expect similar outcomes after transurethral resection of the prostate or photoselective vaporization of the prostate.
|
Significant reduction in gland volume, symptom scores continues to 3 months.
Sep 1, 2008
By:Charles Bankhead
A single injection of a bacterial protoxin activated by prostate-specific antigen led to greater than 50 percent improvement in symptoms within 3 months in a preliminary clinical study of men with benign prostatic hyperplasia.
|
| 
Brings you the latest news and information twice each month.
Urology Times archives are now available on ModernMedicine.com, a new online resource designed to meet the evolving needs of physicians.